Cell-free Enzymatic DNA Synthesis to enable synthetic biology
| Reference number | |
| Coordinator | Moligo Technologies AB |
| Funding from Vinnova | SEK 1 500 000 |
| Project duration | May 2024 - May 2025 |
| Status | Completed |
| Venture | Ground-breaking technology solutions |
| Call | Groundbreaking and scalable technology solutions in 2024 |
Important results from the project
This project led to the development of an in-house, fast and cost-effective DNA assembly technology for the synthesis of long, complex dsDNA templates. With the implementation of this project, Moligo Technologies will become a key global supplier of high quality synthetic DNA, enabling new technologies and therapies in the synthetic biology space. This will also reduce the risk of over-dependency of other European biotech and pharma companies from Chinese and US-based manufacturers.
Expected long term effects
More and more gene based technologies and therapies today rely on high quality DNA molecules, and scale. The development of a DNA assembly technology, for the synthesis of long, complex dsDNA templates, supported by this project, is crucial to develop safer and more accessible cell and gene therapies, to have better access to tools for crops editing for more sustainable agriculture and for the development of more sensitive and cost-effective diagnostics.
Approach and implementation
The project was carried out through a combination of in silico methods and in vitro/in vivo experiments, involving the design of machine learning–based algorithms as well as molecular and synthetic biology approaches, where computational models and experimental data continuously informed each other in an iterative loop. By using these approaches, the project not only achieved its planned milestones but also produced findings that positively influenced other ongoing projects in the company.